Nkarta reports Q1 net loss $26.0M; shares positive AML/NHL clinical data

Nkarta, Inc.

2023-Q1 EPS reported -$0.79

Net loss $26.0M ($0.79/share); cash, equivalents & short-term investments $219.1M at 3/31/22, plus $215.5M net from April offering, pro forma >$400M.
NKX101 Phase 1: 3 of 5 heavily pre-treated AML patients at higher dose achieved complete response; 2 of 3 CRs MRD-negative.
NKX019 Phase 1: 5 of 6 NHL patients responded, 3 CR (including DLBCL and MCL); no CRS, GvHD, or ICANS observed in either study.
Anticipates additional NKX101 and NKX019 dose-escalation data in H2 2022.
Angela Thedinga appointed to Board of Directors in March 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.